Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Kite Pharma
Deal Size : $2,300.0 million
Deal Type : Termination
Gilead's Kite Erodes $2.3B Shoreline Cell Therapy Deal
Details : Kite Pharma has cut off a collaboration with Shoreline Biosciences, ending a research collaboration on off-the-shelf cell therapies.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
September 03, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Kite Pharma
Deal Size : $2,300.0 million
Deal Type : Termination
Lead Product(s) : EDIT-202
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Editas Medicine
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the terms of the agreement, Shoreline will acquire EDIT-202, Editas Medicine’s preclinical multiplexed edited iNK cell medicine for the potential treatment of solid tumors and an additional iNK program under development and certain related manufa...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 19, 2023
Lead Product(s) : EDIT-202
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Editas Medicine
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Development of an iPSC-derived NK cell screening platform for discovery of NK cell optimized Chimeric Antigen Receptors (CARs) for next-generation CAR-NK cell immunotherapies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Kite Pharma
Deal Size : $2,300.0 million
Deal Type : Partnership
Details : The collaboration will leverage Shoreline’s deep expertise in iPSC differentiation and genetic reprogramming in combination with Kite’s extensive cell therapy expertise to develop novel allogeneic candidates for a range of hematologic malignancies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 17, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Kite Pharma
Deal Size : $2,300.0 million
Deal Type : Partnership